

Acadia Pharmaceuticals Inc. (ACAD)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001070494

Acadia Pharmaceuticals Inc.					
ACAD; healthcare					
Grade	A/B	on the A/B boundary of 371 graded peers percentile 17.6; sampling error 2.5 points; lower is stronger			
Rank	66 of 371				
Profitability	C	percentile 53.4			
Solvency	B	percentile 34.8			
Growth and financing	B	percentile 22.8			
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025				
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	\$591M to \$2.67B assets total assets \$1.6B				
Standard universe	inside revenue above \$1M and assets above \$10M				
Warnings	none active not computable: distress, fortress balance sheet				
Inputs computable	8 of 14				
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026				
Last close	\$19.57 2026-10-08; market equity \$3.4B				
Price used in grade	None				

A/B, the bull
on the A/B boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

Rescans on file: A from Mar 21, 2026, A/B from Sep 26, 2026, A from Sep 30, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated

with Parkinson's disease psychosis (PDP).


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 53.4						
Gross profitability		62.8%	32.2%	14.6	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		20.4%	(6.6%)	95.3	811	2025-12-31
Gross margin stability, five years		2.8 pts	2.8 pts	50.4	243	2025-12-31
Solvency, sleeve percentile 34.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		3.79	(0.31)	22.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		3.83x	2.96x	47.3	839	2025-12-31
Growth and financing, sleeve percentile 22.8						
Revenue growth, three-year compound		27.5%	10.0%	23.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		38.6%	2.1%	11.4	704	2025-12-31
Net share issuance, one year		2.2%	2.5%	33.0	634	2026-02-18

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
61	RxSight, Inc. (RXST)	16.2	A	fortress balance sheet
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress balance sheet
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.0	A	
65	Aurinia Pharmaceuticals Inc. (AUPH)	17.3	A	
66	Acadia Pharmaceuticals Inc. (ACAD) <	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.8	A/B	
68	Conmed Corp. (CNMD)	18.1	A/B	
69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet
70	Orthofix Medical Inc. (OFIX)	18.6	A/B	
71	Adma Biologics, Inc. (ADMA)	18.9	A/B	late filer, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	35.5%	8.0%	69
Distance from 52-week high	(36.0%)	(31.4%)	42
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	3.1%	(1.0%)	70
Book value to price	0.39	0.28	60
Sales to price	0.32	0.31	51
Composite equity issuance, five years	7.4%	20.3%	36
Relative strength against the sector, log excess return	0.09	(0.14)	69

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$385.0M

Operating cash flow, four quarters	\$160.3M
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$39.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2025-12-31	2026-02-26	10-K	0001193125-26-072519
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$89.0M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
3	assets	us-gaap:Assets	\$1.6B	2025-12-31	2026-02-26	10-K	0001193125-26-072519
4	net income	us-gaap:NetIncomeLoss	\$391.0M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$109.8M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
6	assets	us-gaap:Assets	\$1.2B	2024-12-31	2026-02-26	10-K	0001193125-26-072519
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$957.8M	2024-12-31	2026-02-26	10-K	0001193125-26-072519
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$81.8M	2024-12-31	2026-02-26	10-K	0001193125-26-072519
9	gross profit	us-gaap:GrossProfit	\$684.8M	2023-12-31	2024-02-28	10-K	0000950170-24-021473
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$726.4M	2023-12-31	2026-02-26	10-K	0001193125-26-072519
11	gross profit	us-gaap:GrossProfit	\$507.1M	2022-12-31	2024-02-28	10-K	0000950170-24-021473
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$517.2M	2022-12-31	2025-02-27	10-K	0000950170-25-029253
13	gross profit	us-gaap:GrossProfit	\$473.3M	2021-12-31	2023-02-28	10-K	0000950170-23-004757
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$484.1M	2021-12-31	2024-02-28	10-K	0000950170-24-021473
15	current assets	us-gaap:AssetsCurrent	\$1.1B	2025-12-31	2026-02-26	10-K	0001193125-26-072519
16	current liabilities	us-gaap:LiabilitiesCurrent	\$277.1M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.8B	2025-12-31	2026-02-26	10-K	0001193125-26-072519
18	operating income	us-gaap:OperatingIncomeLoss	\$104.8M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
19	book equity	us-gaap:StockholdersEquity	\$1.2B	2025-12-31	2026-02-26	10-K	0001193125-26-072519
20	liabilities	us-gaap:Liabilities	\$336.8M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.7M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$157.7M	2024-12-31	2026-02-26	10-K	0001193125-26-072519
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$523,000	2024-12-31	2026-02-26	10-K	0001193125-26-072519
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$16.7M	2023-12-31	2026-02-26	10-K	0001193125-26-072519
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$50,000	2023-12-31	2026-02-26	10-K	0001193125-26-072519
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$114.0M	2022-12-31	2025-02-27	10-K	0000950170-25-029253
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2022-12-31	2025-02-27	10-K	0000950170-25-029253
28	depreciation amortization	us-gaap:Depreciation	\$871,000	2025-12-31	2026-02-26	10-K	0001193125-26-072519
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$188.9M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
30	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$252.1M	2025-12-31	2026-02-26	10-K	0001193125-26-072519
31	current assets	us-gaap:AssetsCurrent	\$938.3M	2024-12-31	2026-02-26	10-K	0001193125-26-072519
32	current liabilities	us-gaap:LiabilitiesCurrent	\$394.9M	2024-12-31	2026-02-26	10-K	0001193125-26-072519
33	assets	us-gaap:Assets	\$749.0M	2023-12-31	2025-02-27	10-K	0000950170-25-029253
34	assets	us-gaap:Assets	\$587.8M	2022-12-31	2024-02-28	10-K	0000950170-24-021473
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	170,494,613	2026-02-18	2026-02-26	10-K	0001193125-26-072519
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	166,788,517	2025-02-18	2025-02-27	10-K	0000950170-25-029253